Written answers
Tuesday, 16 January 2018
Department of Health
Medicinal Products Reimbursement
John Brassil (Kerry, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
971. To ask the Minister for Health if clinical expert opinion will be included in the decision-making process for the reimbursement of Vimizim; if consultation with local expert opinion will also be taken into account by the HSE drugs group; and if he will make a statement on the matter. [1093/18]
Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source
The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.
John Brassil (Kerry, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
972. To ask the Minister for Health his views on whether the current QALY-based system for reimbursing orphan drugs is inappropriate; his plans to engage with key stakeholders to reform the system to take into account evidence from other jurisdictions; and if he will make a statement on the matter. [1094/18]
Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source
The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.
No comments